NASDAQ:STML - Stemline Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.83
+0.30 (1.20%)
Get New Stemline Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STML and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STML

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stemline Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.83.

This chart shows the closing price for STML for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Stemline Therapeutics. This rating has held steady since May 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2020AegisReiterated RatingBuyLow
5/5/2020HC WainwrightDowngradeBuy ➝ Neutral$18.00 ➝ $12.50Low
5/5/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$12.50Low
5/5/2020Alliance Global PartnersDowngradeBuy ➝ Neutral$14.50 ➝ $12.50Low
5/4/2020WedbushDowngradeOutperform ➝ Neutral$11.00 ➝ $12.50Low
5/4/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$10.00 ➝ $12.50N/A
3/27/2020Cantor FitzgeraldReiterated RatingOverweight$18.00 ➝ $10.00Medium
3/26/2020JPMorgan Chase & Co.Lower Price TargetOverweight$9.00 ➝ $8.00Low
3/23/2020AegisReiterated RatingBuy$11.00Low
3/17/2020WedbushLower Price TargetOutperform$14.00 ➝ $11.00High
3/17/2020Piper SandlerLower Price Target$25.00 ➝ $9.00High
3/17/2020HC WainwrightLower Price TargetBuy$20.00 ➝ $18.00High
3/3/2020HC WainwrightReiterated RatingBuy$20.00High
1/21/2020HC WainwrightLower Price TargetBuy$35.00 ➝ $20.00Low
1/16/2020WedbushLower Price TargetOutperform$17.00 ➝ $14.00Low
12/24/2019Cantor FitzgeraldInitiated CoverageOverweight$18.00Low
12/11/2019HC WainwrightReiterated RatingBuy$35.00High
11/25/2019Alliance Global PartnersInitiated CoverageBuy$21.00Medium
11/11/2019HC WainwrightReiterated RatingBuy$35.00High
9/30/2019HC WainwrightReiterated RatingBuy$35.00High
9/18/2019CowenReiterated RatingBuyHigh
8/4/2019CowenReiterated RatingBuyHigh
8/2/2019WedbushUpgradeNeutral ➝ OutperformHigh
6/20/2019HC WainwrightSet Price TargetBuy$35.00High
5/23/2019Roth CapitalReiterated RatingBuyHigh
5/13/2019WedbushDowngradeOutperform ➝ Neutral$18.00High
5/10/2019Roth CapitalSet Price TargetBuy$33.00High
3/18/2019Piper Jaffray CompaniesSet Price TargetBuy$23.00Low
2/6/2019Piper Jaffray CompaniesReiterated RatingOverweightMedium
1/25/2019HC WainwrightReiterated RatingBuy$35.00Medium
12/30/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00High
12/26/2018HC WainwrightReiterated RatingBuy$38.00High
12/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$30.00High
12/23/2018Roth CapitalSet Price TargetBuy$33.00Low
12/21/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00High
12/11/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$17.00Medium
12/7/2018HC WainwrightSet Price TargetBuy$38.00Low
12/2/2018Piper Jaffray CompaniesInitiated CoverageOverweight$12.26Low
12/2/2018Roth CapitalSet Price TargetBuy$33.00Low
11/28/2018HC WainwrightSet Price TargetBuy$38.00High
11/26/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$20.00High
11/21/2018HC WainwrightSet Price TargetBuy$38.00Medium
11/14/2018Roth CapitalSet Price TargetBuy$33.00Low
11/12/2018WedbushReiterated RatingOutperform$22.00High
11/12/2018HC WainwrightSet Price TargetBuy$38.00High
8/10/2018HC WainwrightSet Price TargetBuy$38.00Low
6/18/2018HC WainwrightReiterated RatingBuyLow
6/15/2018CowenReiterated RatingBuyLow
6/12/2018Roth CapitalInitiated CoverageBuy$30.00High
6/6/2018HC WainwrightSet Price TargetBuy$38.00Low
5/29/2018WedbushBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $22.00Low
5/10/2018CowenReiterated RatingBuyMedium
5/10/2018HC WainwrightSet Price TargetBuy$38.00High
5/1/2018HC WainwrightSet Price TargetBuy$38.00Medium
4/6/2018HC WainwrightInitiated CoverageBuy$38.00Low
3/19/2018HC WainwrightSet Price TargetBuy$38.00Low
2/2/2018HC WainwrightReiterated RatingBuy$38.00Low
12/14/2017HC WainwrightSet Price TargetBuy$38.00High
11/10/2017HC WainwrightReiterated RatingBuy$38.00N/A
11/1/2017HC WainwrightBoost Price TargetBuy$34.00 ➝ $38.00N/A
10/31/2017CowenReiterated RatingBuyN/A
9/12/2017HC WainwrightReiterated RatingBuy$34.00Medium
8/9/2017HC WainwrightSet Price TargetBuy$34.00High
6/14/2017CowenReiterated RatingBuyHigh
5/25/2017Jefferies Financial GroupReiterated RatingBuy$16.00Medium
5/15/2017HC WainwrightReiterated RatingBuyMedium
5/12/2017CowenReiterated RatingBuyLow
5/11/2017WedbushBoost Price TargetOutperform$33.00 ➝ $40.00High
3/28/2017HC WainwrightReiterated RatingBuy$34.00Low
3/25/2017WedbushReiterated RatingOutperform$11.00Low
3/23/2017CowenReiterated RatingBuyLow
3/20/2017LADENBURG THALM/SH SHSet Price TargetBuy$41.00Medium
3/20/2017HC WainwrightSet Price TargetBuy$34.00High
3/17/2017WedbushReiterated RatingOutperform$11.00High
2/27/2017HC WainwrightSet Price TargetBuy$34.00N/A
2/6/2017LADENBURG THALM/SH SHReiterated RatingBuyN/A
2/6/2017WedbushLower Price TargetOutperform$19.00 ➝ $11.00N/A
2/3/2017Jefferies Financial GroupSet Price TargetBuy$16.00N/A
2/2/2017CowenReiterated RatingBuyN/A
1/8/2017HC WainwrightSet Price TargetBuy$34.00N/A
1/6/2017WedbushReiterated RatingOutperform$19.00 ➝ $15.00N/A
12/12/2016HC WainwrightReiterated RatingBuy$34.00N/A
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/A
12/6/2016WedbushReiterated RatingOutperform$15.00N/A
12/4/2016Jefferies Financial GroupSet Price TargetBuy$23.00N/A
11/23/2016Roth CapitalReiterated RatingBuy$32.00N/A
11/21/2016HC WainwrightReiterated RatingBuyN/A
11/11/2016Roth CapitalReiterated RatingBuy$32.00N/A
11/8/2016WedbushReiterated RatingOutperform$15.00N/A
8/25/2016Roth CapitalReiterated RatingBuy$32.00N/A
8/23/2016WedbushReiterated RatingOutperform$15.00N/A
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
(Data available from 7/23/2016 forward)
Stemline Therapeutics logo
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Read More

Today's Range

Now: $11.83
Low: $11.83
High: $11.83

50 Day Range

MA: $11.83
Low: $11.83
High: $11.83

52 Week Range

Now: $11.83
Low: $3.21
High: $18.22

Volume

1,084 shs

Average Volume

1,524,566 shs

Market Capitalization

$621.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Stemline Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Stemline Therapeutics in the last twelve months:
View the latest analyst ratings for STML.

What is the current price target for Stemline Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Stemline Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Stemline Therapeutics in the next year.
View the latest price targets for STML.

What is the current consensus analyst rating for Stemline Therapeutics?

Stemline Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STML.

What other companies compete with Stemline Therapeutics?

How do I contact Stemline Therapeutics' investor relations team?

Stemline Therapeutics' physical mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company's listed phone number is 646-502-2311 and its investor relations email address is [email protected] The official website for Stemline Therapeutics is www.stemline.com.